The burden of psoriatic arthritis in the biologics era: data from the Belgian Epidemiological Psoriatic Arthritis Study.

Kurt de VlamSerge SteinfeldAdrien Nzeusseu ToukapFilip van den BoschRik JoosPiet GeysensHermine LeroiRik Loriesnull null

Published in: Rheumatology (Oxford, England) (2021)

Despite the availability of different treatment options, including biologics (anti-TNF), a substantial number of patients have active disease and have a high disease burden.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
rheumatoid arthritis
risk factors
patient reported outcomes
artificial intelligence